Ultragenyx Pharmaceutical (NASDAQ:RARE) Hits New 1-Year Low – Should You Sell?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $36.71 and last traded at $37.08, with a volume of 184337 shares changing hands. The stock had previously closed at $38.69.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Wedbush reissued a “neutral” rating and issued a $48.00 price target (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 13th. HC Wainwright restated a “buy” rating and issued a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Friday, February 14th. Piper Sandler decreased their target price on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an “overweight” rating on the stock in a research report on Monday, March 17th. Cantor Fitzgerald restated an “overweight” rating and set a $118.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 26th. Finally, Canaccord Genuity Group boosted their target price on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a “buy” rating in a research note on Tuesday, February 18th. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat, Ultragenyx Pharmaceutical presently has an average rating of “Moderate Buy” and an average target price of $91.71.

Ultragenyx Pharmaceutical Trading Down 4.1 %

The company’s fifty day simple moving average is $41.78 and its 200 day simple moving average is $47.15. The firm has a market capitalization of $3.43 billion, a P/E ratio of -5.85 and a beta of 0.67.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.32) by ($0.07). The company had revenue of $164.88 million during the quarter, compared to analysts’ expectations of $163.23 million. Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. On average, analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Insider Activity at Ultragenyx Pharmaceutical

In other news, CAO Theodore Alan Huizenga sold 967 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total value of $40,710.70. Following the sale, the chief accounting officer now directly owns 50,265 shares of the company’s stock, valued at $2,116,156.50. The trade was a 1.89 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Thomas Richard Kassberg sold 6,028 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total value of $253,778.80. Following the transaction, the executive vice president now owns 265,238 shares of the company’s stock, valued at $11,166,519.80. The trade was a 2.22 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 136,370 shares of company stock worth $5,751,499 over the last ninety days. 5.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of hedge funds have recently bought and sold shares of RARE. Smartleaf Asset Management LLC raised its holdings in Ultragenyx Pharmaceutical by 259.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 493 shares during the last quarter. True Wealth Design LLC bought a new position in Ultragenyx Pharmaceutical in the 3rd quarter valued at approximately $43,000. Aster Capital Management DIFC Ltd bought a new position in Ultragenyx Pharmaceutical in the 4th quarter valued at approximately $35,000. Human Investing LLC bought a new stake in shares of Ultragenyx Pharmaceutical in the 4th quarter worth $42,000. Finally, Wilmington Savings Fund Society FSB purchased a new position in shares of Ultragenyx Pharmaceutical in the third quarter worth $83,000. Institutional investors own 97.67% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.